[18F]FDG PET/MRI in the follow-up of hepatocellular carcinoma after liver transplantation.

Authors:
Zucchetta P; Lacognata C; Girardi F; Spimpolo A; Crimì F and 6 more

Journal:
Nucl Med Commun

Publication Year: 2022

DOI:
10.1097/MNM.0000000000001518

PMCID:
PMC9897275

PMID:
35019883

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Nucl Med Commun

Abbreviation: Nucl Med Commun

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Nuclear Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Safety, biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 99m Tc-maraciclatide in …
Gibbons T; Perkins A; Barnett J. (2024) - Transparency Score: 3/6
18 F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immuno…
Feng Y; Wang P; Chen Y and 1 more (2023) - Transparency Score: 3/6
BNMS UK PET standards.
Cook GJR; Dickson J; Chicklore S and 6 more (2023) - Transparency Score: 2/6
Clinical impact of molecular breast imaging as adjunct diagnostic modality in evaluation of indeter…
van Loevezijn AA; Corion CLS; Zeillemaker AM and 7 more (2023) - Transparency Score: 2/6
Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D …
Uijen MJM; Privé BM; van Herpen CML and 7 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Acknowledgements: Conflicts of interest: There are no conflicts of interest."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025